[Autoimmune myopathy associated with statin use].

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Statins are widely prescribed cholesterol-lowering drugs.
• Statin toxicity commonly affects muscles.
• A less recognized effect is statin-induced autoimmune myopathy.

Purpose of the Study:

• To elucidate the characteristics of statin-associated autoimmune myopathy.
• To highlight the diagnostic markers for this condition.

Main Methods:

• Review of clinical presentations of statin-associated autoimmune myopathy.
• Analysis of serological markers, specifically anti-3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) antibodies.
• Examination of muscle biopsy findings.

Main Results:

• Statin-associated autoimmune myopathy presents with proximal muscle weakness.
• Presence of antibodies to HMGCR in patient serum is a key indicator.
• Muscle biopsy reveals necrosis but lacks significant lymphocytic infiltration.

Conclusions:

• Statin-associated autoimmune myopathy is a distinct autoimmune condition triggered by statin use.
• Diagnosis relies on clinical symptoms, specific autoantibodies, and biopsy findings.
• Recognition of this myopathy is crucial for appropriate patient management.